Topeline data were announced from a phase 3 trial evaluating SB-01 for intradiscal treatment of patients with CLBP associated with DDD.

Disc Medicine has charted a route to market for its bitopertin drug for rare disease erythropoietic protoporphyria.

Mesenchymal stem cells can self-renew by dividing and can differentiate into multiple tissues including bone, cartilage, muscle and fat cells, and connective tissue.